{
    "id": "5c674eac7c78d6947100001b",
    "question": "Has Hesperidin any role as a Neuroprotective Agent?",
    "options": {
        "A": "yes",
        "B": "no"
    },
    "answer": "A",
    "predict": "{\"step_by_step_thinking\": \"To answer this question, we need to analyze the provided documents and look for any information related to Hesperidin and its potential role as a neuroprotective agent. From Document [12], we know that flavonoids, including Hesperidin, have antioxidant activity and affect cell signaling. However, the document does not explicitly state that Hesperidin has been investigated as a neuroprotective agent. From Document [10], we can see that flavonoids, including diosmin, hesperidin, and micronized purified flavonoid fraction, have been touted to have venoconstrictive and anti-inflammatory properties. Although there is some evidence that flavonoids may have a role in the prevention of several chronic diseases, including neurodegenerative disease, diabetes, and osteoporosis, the document does not provide any specific information about Hesperidin's role as a neuroprotective agent. From Document [22], we can see that there is some evidence that polyglutamine expansions are implicated in several neurodegenerative diseases, and treatments that block their effects on cellular function may be broadly effective in several degenerative diseases. However, this document does not mention Hesperidin. From Document [23], we can see that there is some evidence that aggregated amyloid is not solely responsible for Alzheimer disease, and that amyloid may accelerate degeneration of neurons. However, this document does not mention Hesperidin. From Document [24], we can see that excitotoxicity refers to neuronal cell death caused by activation of excitatory amino acid receptors, and that glutamate receptor antagonists are effective in preventing focal ischemia. However, this document does not mention Hesperidin. From Document [25], we can see that nerve growth factors such as brain-derived neurotrophic factor (BDNF) are critical in the regulation of neural plasticity, resilience, and neurogenesis. However, this document does not mention Hesperidin. From Document [26], we can see that the role of aluminum in the genesis of neurofibrillary tangles has never been validated, and that estrogen by postmenopausal women or anti-inflammatory agents in men or women may delay the onset of the disease or reduce its occurrence. However, this document does not mention Hesperidin. From Document [27], we can see that amyloid may accelerate degeneration of neurons and once dementia is established, there may be little additional accumulation of amyloid. However, this document does not mention Hesperidin. From Document [28], we can see that the effects of a drug on the CNS require an understanding of the multiple levels of brain organization, from genes to circuits to behavior. However, this document does not mention Hesperidin. From Document [29], we can see that excitotoxicity refers to neuronal cell death caused by activation of excitatory amino acid receptors, and that glutamate receptor antagonists are effective in preventing focal ischemia. However, this document does not mention Hesperidin. From Document [30], we can see that BDNF is thought to exert its influence on neuronal survival and growth effects by activating the tyrosine kinase receptor B in both neurons and glia. However, this document does not mention Hesperidin. From Document [31], we can see that the human brain contains about 100 billion interconnected neurons surrounded by various supporting glial cells, and that connections among neurons both within and between these clusters form the circuitry that regulates information flow through the CNS. However, this document does not mention Hesperidin. After analyzing all the documents, it appears that there is no evidence to suggest that Hesperidin has a role as a neuroprotective agent.\", \"answer_choice\": \"B\"}",
    "snippets": [
        {
            "id": "Pharmacology_Katzung_3040",
            "title": "Pharmacology_Katzung",
            "content": "Among the compounds that have been investigated as potential neuroprotective agents to slow disease progression are antioxidants, antiapoptotic agents, glutamate antagonists, intraparenchymally administered glial-derived neurotrophic factor, and anti-inflammatory drugs. None of these agents has been shown to be effective in this context, however, and their use for therapeutic purposes is not indicated at this time. Coenzyme Q10, creatine, pramipexole, and pioglitazone have not been found to be effective despite early hopes to the contrary. The possibility that rasagiline has a protective effect was discussed earlier. Active and passive immunization against \u03b1-synuclein is being explored."
        },
        {
            "id": "Neurology_Adams_6389",
            "title": "Neurology_Adams",
            "content": "of ischemia and the production of destructive oxygen-free radicals were referred to earlier. Among the numerous \u201cbrain-sparing\u201d agents that have been tried in an attempt to reduce the size of infarction, certain ones have had erratic results in large randomized trials. Two trials, for example, gave initially promising results and later proved ineffective (Shuaib et al). These agents were of interest because they can be administered up to several hours after the stroke (continuing for 72 h). So far, the results of neuroprotective agents in stroke have been discouraging."
        },
        {
            "id": "InternalMed_Harrison_30363",
            "title": "InternalMed_Harrison",
            "content": "A list of the major drugs and available dosage strengths is provided in Table 449-5. Despite the many therapeutic agents available for the treatment of PD, patients continue to experience disease progression with intolerable disability. A neuroprotective therapy that slows or stops disease progression remains the major unmet therapeutic need in PD. As noted above, trials of certain drugs (e.g., selegiline and rasagiline) have provided positive results consistent with a disease-modifying effect. However, it is not possible to determine if the positive results were due to neuroprotection with slowing of disease progression or confounding symptomatic effects that mask ongoing progression. CoQ10, a mitochondrial bioenhancer and antioxidant, attracted attention with a positive preliminary trial, but this was not replicated in larger double-blind studies."
        },
        {
            "id": "Neurology_Adams_8687",
            "title": "Neurology_Adams",
            "content": "Neuroprotective agents An additional approach has been to initiate treatment early in the course of the disease with a monoamine oxidase-B inhibitor (MAO-B inhibitor), with the aim of reducing oxidative stress in dopaminergic neurons. The DTAATOP trial conducted by The Parkinson Study Group (1989) reported a slowing of disease progression but later followup showed little difference between treated and untreated groups. Other agents in this class, notably rasagiline, have given similar mixed results in brief studies including the ADAGIO trial reported by Olanow and coworker. The difficulty in assessing the benefit of these agents has to do with their mild but definite symptomatic benefit on motor function. A long-term study has reported that early initiation of treatment with bromocriptine (now little used) did not reduce mortality or motor disability over 14 years and that any reduction in motor complications was unsustained (Katzenschlager et al). Nonetheless, we often institute one"
        },
        {
            "id": "InternalMed_Harrison_30326",
            "title": "InternalMed_Harrison",
            "content": "Each of these mechanisms offers a potential target for neuroprotective drugs. However, it is not clear which of these factors is primary, if the mechanism is the same in each individual case, if they act by way of a network such that a cocktail of agents might be required to provide neuroprotection, or if the findings to date merely represent epiphenomena unrelated to the true cause of cell death that remains undiscovered (Fig. 449-4). Gene mutations may not cause all cases of PD, but may be helpful in pointing to specific pathogenic pathways and mechanisms that are central to a neurodegenerative process that might be relevant to all forms of the disease. To date, most interest has focused on pathways implicated by mutations in \u03b1-synuclein, LRRK2, and PINK1/Parkin."
        },
        {
            "id": "InternalMed_Harrison_5684",
            "title": "InternalMed_Harrison",
            "content": "(human and animal) studies, flavonoids have been postulated to play a role in the prevention of several chronic diseases, including neurodegenerative disease, diabetes, and osteoporosis. The ultimate importance and usefulness of these compounds against human disease have not been demonstrated."
        },
        {
            "id": "InternalMed_Harrison_29909",
            "title": "InternalMed_Harrison",
            "content": "Neuroprotection is the concept of providing a treatment that prolongs the brain\u2019s tolerance to ischemia. Drugs that block the excitatory amino acid pathways have been shown to protect neurons and glia in animals, but despite multiple human trials, they have not yet been proven to be beneficial. Hypothermia is a powerful neuroprotective treatment in patients with cardiac arrest (Chap. 330) and is neuroprotective in animal models of stroke, but it has not been adequately studied in patients with ischemic stroke and is associated with an increase in pneumonia rates that could adversely impact stroke outcomes."
        },
        {
            "id": "Pharmacology_Katzung_7101",
            "title": "Pharmacology_Katzung",
            "content": "2. Metabolic effects\u2014Antioxidant and radical-scavenging properties have been observed for the flavonoid fraction of ginkgo as well as some of the terpene constituents. In vitro, ginkgo has been reported to have superoxide dismutase-like activity and superoxide anionand hydroxyl radical-scavenging properties. The flavonoid fraction has also been observed to have antiapoptotic properties. In some studies, it has also demonstrated a protective effect in limiting free radical formation in animal models of ischemic injury and in reducing markers of oxidative stress in patients undergoing coronary artery bypass surgery. 3."
        },
        {
            "id": "InternalMed_Harrison_30354",
            "title": "InternalMed_Harrison",
            "content": "Interest in MAO-B inhibitors has also focused on their potential to have disease-modifying effects. MPTP toxicity can be prevented experimentally by coadministration of an MAO-B inhibitor that blocks its conversion to the toxic pyridinium ion MPP+. MAO-B inhibitors also have the potential to block the oxidative metabolism of dopamine and prevent oxidative stress. In addition, both selegiline and rasagiline incorporate a propargyl ring within their molecular structure that provides antiapoptotic effects in laboratory models. The DATATOP study showed that selegiline significantly delayed the time until the emergence of disability, necessitating the introduction of levodopa, in untreated PD patients. However, it could not be determined whether this was due to a neuroprotective effect that slowed disease progression or a symptomatic effect that merely masked ongoing neurodegeneration. More recently, the ADAGIO study demonstrated that early treatment with rasagiline 1 mg/d, but not 2 mg/d,"
        },
        {
            "id": "Pharmacology_Katzung_7112",
            "title": "Pharmacology_Katzung",
            "content": "dopamine in the cerebral cortex. Miscellaneous effects included antioxidant activity; anti-inflammatory effects (inhibited tumor necrosis factor-\u03b1, interleukin-1\u03b2, and vascular and intracellular cell adhesion molecules); antistress activity (ie, stimulated pituitary-adrenocortical system, agonist at glucocorticoid receptor); analgesia (inhibited substance P); vasoregulatory effects (increased endothelial nitric oxide, inhibited prostacyclin production); cardioprotective activity (reduced ventricular remodeling and cardiac hypertrophy in animal models of myocardial ischemia); antiplatelet activity; improved glucose homeostasis (reduced cell death in pancreatic beta cells; increased insulin release, number of insulin receptors, and insulin sensitivity); and anticancer properties (reduced tumor angiogenesis, increased tumor cell apoptosis). Such extensive claims naturally evoke skepticism and require careful replication."
        },
        {
            "id": "InternalMed_Harrison_19854",
            "title": "InternalMed_Harrison",
            "content": "There are no drugs approved by the U.S. Food and Drug Administration for the treatment of chronic venous insufficiency. Diuretics may reduce edema, but at the risk of volume depletion and compromise in renal function. Topical steroids may be used for a short period of time to treat inflammation associated with stasis dermatitis. Several herbal supplements, such as horse chestnut seed extract (aescin); flavonoids including diosmin, hesperidin, or the two combined as micronized purified flavonoid fraction; and French maritime pine bark extract, are touted to have venoconstrictive and anti-inflammatory properties. Although meta-analyses have suggested that aescin reduces edema, pruritus, and pain and that micronized purified flavonoid fraction in conjunction with compression therapy facilitates venous ulcer healing, there is insufficient evidence to recommend the general use of these substances in patients with chronic venous insufficiency."
        },
        {
            "id": "InternalMed_Harrison_30395",
            "title": "InternalMed_Harrison",
            "content": "FIGURE 449-7 Treatment options for the management of Parkinson\u2019s disease (PD). Decision points include: (1) Introduction of a neuroprotective therapy: No drug has been established to have or is currently approved for neuroprotection or disease modification, but there are several agents that have this potential based on laboratory and preliminary clinical studies (e.g., rasagiline 1 mg/d, coenzyme Q10 1200 mg/d, the dopamine agonists ropinirole, and pramipexole). (2) When to initiate symptomatic therapy: There is a trend toward initiating therapy at the time of diagnosis or early in the course of the disease because patients may have some disability even at an early stage, and there is the possibility that early treatment may preserve beneficial compensatory mechanisms; however, some experts recommend waiting until there is functional disability before initiating therapy. (3) What therapy to initiate: Many experts favor starting with a monoamine oxidase type B (MAO-B) inhibitor in"
        },
        {
            "id": "InternalMed_Harrison_5683",
            "title": "InternalMed_Harrison",
            "content": "Flavonoids constitute a large family of polyphenols that contribute to the aroma, taste, and color of fruits and vegetables. Major groups of dietary flavonoids include anthocyanidins in berries; catechins in green tea and chocolate; flavonols (e.g., quercitin) in broccoli, kale, leeks, onions, and the skins of grapes and apples; and isoflavones (e.g., genistein) in legumes. Isoflavones have a low bioavailability and are partially metabolized by the intestinal flora. The dietary intake of flavonoids is estimated at 10\u2013100 mg/d; this figure is almost certainly an underestimate attributable to a lack of information on their concentrations in many foods. Several flavonoids have antioxidant activity and affect cell signaling. From observational epidemiologic studies and limited clinical (human and animal) studies, flavonoids have been postulated to play a role in the prevention of several chronic diseases, including neurodegenerative disease, diabetes, and osteoporosis. The ultimate"
        },
        {
            "id": "InternalMed_Harrison_29700",
            "title": "InternalMed_Harrison",
            "content": "Interestingly, in experimental models of Huntington\u2019s disease and cerebellar degeneration, protein aggregates are not well correlated with neuronal death and may be protective. A substantial body of evidence suggests that the mutant proteins with polyglutamine expansions in these diseases bind to transcription factors and that this contributes to disease pathogenesis. In Huntington\u2019s disease, there is dysfunction of the transcriptional co-regulator, PGC-1\u03b1, a key regulator of mitochondrial biogenesis. There is evidence that impaired function of PGC-1\u03b1 is also important in both Parkinson\u2019s disease and AD, making it an attractive target for treatments. Agents that upregulate gene transcription are neuroprotective in animal models of these diseases. A number of compounds have been developed to block \u03b2-amyloid production and/or aggregation, and these agents are being studied in early clinical trials in humans. Another approach under investigation is immunotherapy with antibodies that bind"
        },
        {
            "id": "Pharmacology_Katzung_7111",
            "title": "Pharmacology_Katzung",
            "content": "An extensive literature exists on the potential pharmacologic effects of ginsenosides. Unfortunately, the studies differ widely in the species of Panax used, the ginsenosides studied, the degree of purification applied to the extracts, the animal species studied, the doses or concentrations involved, and the measurements used to evaluate the responses. Reported beneficial pharmacologic effects include modulation of immune function (induced mRNA expression for interleukins-2 and -1\u03b1, interferon-\u03b3, and granulocytemacrophage colony-stimulating factor; activated B and T cells, natural killer cells, and macrophages). Central nervous system effects included increased proliferating ability of neural progenitors and increased central levels of acetylcholine, serotonin, nor-epinephrine, and dopamine in the cerebral cortex. Miscellaneous effects included antioxidant activity; anti-inflammatory effects (inhibited tumor necrosis factor-\u03b1, interleukin-1\u03b2, and vascular and intracellular cell"
        },
        {
            "id": "Pharmacology_Katzung_7102",
            "title": "Pharmacology_Katzung",
            "content": "3. Central nervous system effects\u2014In aged animal models, chronic administration of ginkgo for 3\u20134 weeks led to modifications in central nervous system receptors and neurotransmitters. Receptor densities increased for muscarinic, \u03b12, and 5-HT1a receptors, and decreased for \u03b2 adrenoceptors. Increased serum levels of acetylcholine and norepinephrine and enhanced synaptosomal reuptake of serotonin and dopamine have also been reported. Additional possible effects include inhibition of amyloid-beta fibril formation and protective effects of Egb761 on hippocampal neurons against cell death induced by beta-amyloid."
        },
        {
            "id": "Neurology_Adams_9085",
            "title": "Neurology_Adams",
            "content": "Vasodilator drugs, glutamate blockers, opiate antagonists, and calcium channel blockers have been of no proven benefit despite their theoretical appeal and some experimental successes. Corticosteroids ostensibly help to allay brain (possibly cellular) swelling, but, again, their therapeutic benefit has not been evident in clinical trials."
        },
        {
            "id": "Pharmacology_Katzung_6651",
            "title": "Pharmacology_Katzung",
            "content": "exquisitely sensitive to the central nervous system toxicities of drugs with antimuscarinic effects. Some evidence implicates excess excitation by glutamate as a contributor to neuronal death. In addition, abnormalities of mitochondrial function may contribute to neuronal death."
        },
        {
            "id": "InternalMed_Harrison_29644",
            "title": "InternalMed_Harrison",
            "content": "bind to and sequester transcription factors. A critical transcription factor for neuronal survival is CREB (cyclic adenosine monophosphate responsive element-binding) protein, which also plays an important role in memory in the hippocampus. The regulatory gene repressor element 1-silencing transcription factor (REST) coordinates the expression of neuroprotective stress genes during normal aging. It turns off genes involved in cell death and pathology and boosts protective factors. High levels of REST are associated with normal cognition even in the presence of both amyloid plaques and neurofibrillary tangles. Although REST increases with normal aging, it fails to increase in the nucleus in patients with Alzheimer\u2019s disease and is found clumped with amyloid in autophagosomes."
        },
        {
            "id": "Pharmacology_Katzung_3012",
            "title": "Pharmacology_Katzung",
            "content": "Pramipexole is not an ergot derivative, but it has preferential affinity for the D3 family of receptors. It is effective as mono-therapy for mild parkinsonism and is also helpful in patients with advanced disease, permitting the dose of levodopa to be reduced and smoothing out response fluctuations. Pramipexole may ameliorate affective symptoms. A possible neuroprotective effect has been suggested by its ability to scavenge hydrogen peroxide and enhance neurotrophic activity in mesencephalic dopaminergic cell cultures."
        },
        {
            "id": "InternalMed_Harrison_29676",
            "title": "InternalMed_Harrison",
            "content": "CELL DEATH: EXCITOTOXICITY AND APOPTOSIS"
        },
        {
            "id": "Pharmacology_Katzung_7176",
            "title": "Pharmacology_Katzung",
            "content": "Sharma M et al: Bactericidal and anti-inflammatory properties of a standardized echinacea extract (Echinaforce): Dual actions against respiratory bacteria. Phytomedicine 2010;17:563. Sharma M et al: The efficacy of echinacea in a 3-D tissue model of human airway epithelium. Phytother Res 2010;24:900. Shi C et al: Ginkgo biloba extract in Alzheimer\u2019s disease: From action mechanisms to medical practice. Int J Mol Sci 2010;11:107. Tacklind J et al: Serenoa repens for benign prostatic hyperplasia. Cochrane Database Syst Rev 2012;12:CD001423. Tan MS et al: Efficacy and adverse effects of ginkgo biloba for cognitive impairment and dementia: a systematic review and meta-analysis. J Alzheimers Dis 2015;43:589. Van Vijven JP et al: Symptomatic and chondroprotective treatment with collagen derivatives in osteoarthritis: A systematic review. Osteoarthritis Cartilage 2012;20:809."
        },
        {
            "id": "Neurology_Adams_8576",
            "title": "Neurology_Adams",
            "content": "the concept that the polyglutamine complex renders certain cell types unduly sensitive to glutamate-mediated excitotoxicity. Two mechanisms have been proposed based on an interruption of protein transcription by the binding of mutant huntingtin to transcription proteins or that mitochondrial dysfunction occurs directly or through the same transcriptional mechanism, as summarized by Greenamyre. Because polyglutamine expansions are implicated in several neurodegenerative diseases (reviewed in corresponding sections of this chapter), treatments that block their effects on cellular function may be broadly effective in several degenerative diseases."
        },
        {
            "id": "Pharmacology_Katzung_3022",
            "title": "Pharmacology_Katzung",
            "content": "Rasagiline, another monoamine oxidase B inhibitor, is more potent than selegiline in preventing MPTP-induced parkinsonism and is being used for early treatment in patients with mild symptoms. The standard dosage is 1 mg/d. Rasagiline is also used as adjunctive therapy at a dosage of 0.5 or 1 mg/d to prolong the effects of carbidopa-levodopa in patients with advanced disease and response fluctuations. A large double-blind, placebo-controlled, delayed-start study (the ADAGIO trial) to evaluate whether it had neuroprotective benefit (ie, slowed the disease course) yielded unclear results: a daily dose of 1 mg met all the end points of the study and did seem to slow disease progression, but a 2-mg dose failed to do so. These findings are difficult to explain and the decision to use rasagiline for neuroprotective purposes therefore remains an individual one."
        },
        {
            "id": "Neurology_Adams_6229",
            "title": "Neurology_Adams",
            "content": "The extent of neural tissue dysfunction is not dictated solely by the activation of these mechanisms in neurons. It is now clear that toxic influences are exerted on oligodendroglial cells in white matter during ischemia and on astrocytic cells that support neurons. Moreover, injury to both neurons and astroyctes is augmented by an inflammatory response that activates endothelial cells to express cell adhesion molecules that attract additional inflammatory cells and upregulate levels of inflammatory proteases (e.g., metalloproteases) and cytokines (e.g., interleukins and chemokines). These events are summarized in the review by Lo and coworkers."
        },
        {
            "id": "Pharmacology_Katzung_6652",
            "title": "Pharmacology_Katzung",
            "content": "Many methods of treatment of Alzheimer\u2019s disease have been explored (Table 60\u20133). Much attention has been focused on the cholinomimetic drugs because of the evidence of loss of cholinergic neurons noted earlier. Monoamine oxidase (MAO) type B inhibition with selegiline (l-deprenyl) has been suggested to have some beneficial effects. One drug that inhibits N-methyld-aspartate (NMDA) glutamate receptors is available (see below), and \u201campakines,\u201d substances that facilitate synaptic activity at glutamate AMPA receptors, are under intense study. Some evidence suggests that lipid-lowering statins are beneficial. So-called cerebral vasodilators are ineffective."
        },
        {
            "id": "Neurology_Adams_8496",
            "title": "Neurology_Adams",
            "content": "The role of aluminum in the genesis of neurofibrillary tangles, as was once proposed, has never been validated. It has been suggested that the use of estrogen by postmenopausal women or of antiinflammatory agents in men or women delayed the onset of the disease or reduced its occurrence, but neither of these have been corroborated by other studies."
        },
        {
            "id": "Neurology_Adams_8485",
            "title": "Neurology_Adams",
            "content": "suggesting that aggregated amyloid is in some way a protective mechanism of cells. It seems most likely that amyloid alone is not solely responsible for Alzheimer disease, particularly in cases of late-life onset. Amyloid may accelerate degeneration of neurons and once dementia is established, there may be little additional accumulation of amyloid."
        },
        {
            "id": "Pharmacology_Katzung_2186",
            "title": "Pharmacology_Katzung",
            "content": "act on a much slower time scale and modulate the rate at which the neuron discharges. For example, some types of potassium channels opened by depolarization of the cell result in slowing of further depolarization and act as a brake to limit further action potential discharge. Plant and animal toxins that target various voltage-gated ion channels have been invaluable for studying the functions of these channels (see Box: Natural Toxins: Tools for Characterizing Ion Channels; Table 21\u20131)."
        },
        {
            "id": "InternalMed_Harrison_29677",
            "title": "InternalMed_Harrison",
            "content": "Excitotoxicity refers to neuronal cell death caused by activation of excitatory amino acid receptors (Fig. 444e-4). Compelling evidence for a role of excitotoxicity, especially in ischemic neuronal injury, is derived from experiments in animal models. Experimental models of stroke are associated with increased extracellular concentrations of the excitatory amino acid neurotransmitter glutamate, and neuronal damage is attenuated by denervation of glutamate-containing neurons or the administration of glutamate receptor antagonists. The distribution of cells sensitive to ischemia corresponds closely with that of N-methyld-aspartate (NMDA) receptors (except for cerebellar Purkinje cells, which are vulnerable to hypoxia-ischemia but lack NMDA receptors); and competitive and noncompetitive NMDA antagonists are effective in preventing focal ischemia. In global cerebral ischemia, non-NMDA receptors (kainic acid and \u03b1-amino-3-hydroxyl-5-methyl-4-isoxazolepropionate [AMPA]) are activated, and"
        },
        {
            "id": "Pharmacology_Katzung_3241",
            "title": "Pharmacology_Katzung",
            "content": "There is substantial evidence that nerve growth factors such as brain-derived neurotrophic factor (BDNF) are critical in the regulation of neural plasticity, resilience, and neurogenesis. The evidence suggests that depression is associated with the loss of neurotrophic support and that effective antidepressant therapies increase neurogenesis and synaptic connectivity in cortical areas such as the hippocampus. BDNF is thought to exert its influence on neuronal survival and growth effects by activating the tyrosine kinase receptor B in both neurons and glia (Figure 30\u20131)."
        },
        {
            "id": "Pharmacology_Katzung_2178",
            "title": "Pharmacology_Katzung",
            "content": "A full appreciation of the effects of a drug on the CNS requires an understanding of the multiple levels of brain organization, from genes to circuits to behavior. This chapter provides an introduction to the functional organization of the CNS and its synaptic transmitters as a basis for understanding the actions of the drugs described in the following chapters. The CNS is composed of the brain and spinal cord and is responsible for integrating sensory information and generating motor output and other behaviors needed to successfully interact with the environment and enhance species survival. The human brain contains about 100 billion interconnected neurons surrounded by various supporting glial cells. Throughout the CNS, neurons are either clustered into groups called nuclei or are present in layered structures such as the cerebellum or hippocampus. Connections among neurons both within and between these clusters form the circuitry that regulates information flow through the CNS."
        }
    ],
    "scores": [
        0.036386465029710276,
        0.035711465832376596,
        0.025776075776075776,
        0.025055984358481772,
        0.019237883832778392,
        0.018596642272922945,
        0.018442971273159952,
        0.018404390037990714,
        0.01771910127633985,
        0.017555859553123575,
        0.017175291169099216,
        0.01713418160786582,
        0.01675099138520443,
        0.016739039081103795,
        0.01631124650926631,
        0.01611875637104995,
        0.016001024065540194,
        0.015302089215132693,
        0.014843410178338408,
        0.014060606060606062,
        0.0139817911557042,
        0.01358622545063223,
        0.013558000519795547,
        0.013483552780417176,
        0.013458110516934046,
        0.013430477528089887,
        0.01329225352112676,
        0.013002220876236623,
        0.012993999586178358,
        0.012833696680514994,
        0.012133100842778263,
        0.012077898874397
    ]
}